IgA2 Antibodies against SARS-CoV-2 Correlate with NET Formation and Fatal Outcome in Severely Diseased COVID-19 Patients
暂无分享,去创建一个
M. Neurath | G. Schett | H. Hackstein | M. Herrmann | J. Knopf | L. Munoz | M. Leppkes | A. Kremer | S. Achenbach | U. Steffen | H. Pfeiffer | A. Lindemann | Léonie A N Staats | Julia Fürst | Jasmin Knopf | Aylin Lindemann
[1] J. Crothers,et al. Kinetics and isotype assessment of antibodies targeting the spike protein receptor‐binding domain of severe acute respiratory syndrome‐coronavirus‐2 in COVID‐19 patients as a function of age, biological sex and disease severity , 2020, Clinical & translational immunology.
[2] P. Saldiva,et al. SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology , 2020, The Journal of experimental medicine.
[3] M. Neurath,et al. Vascular occlusion by neutrophil extracellular traps in COVID-19 , 2020, EBioMedicine.
[4] M. Rudelius,et al. Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy , 2020, Circulation.
[5] N. Zhong,et al. Characteristics and roles of severe acute respiratory syndrome coronavirus 2‐specific antibodies in patients with different severities of coronavirus 19 , 2020, Clinical and experimental immunology.
[6] L. Risch,et al. Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies , 2020, medRxiv.
[7] Galit Alter,et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection , 2020, medRxiv.
[8] R. Sanders,et al. Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses , 2020, bioRxiv.
[9] D. Unutmaz,et al. Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19 , 2020, medRxiv.
[10] C. Takiya,et al. The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19) , 2020, Scientific Reports.
[11] Robert A. Campbell,et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome , 2020, Blood.
[12] J. Pawlotsky,et al. SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients , 2020, Intensive Care Medicine.
[13] John D Lambris,et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis , 2020, medRxiv.
[14] J. Pačes,et al. COVID-19 and the immune system. , 2020, Physiological research.
[15] Yajuan Li,et al. Serum IgA, IgM, and IgG responses in COVID-19 , 2020, Cellular & Molecular Immunology.
[16] N. Zhong,et al. Characteristics and roles of SARS-CoV-2 specific antibodies in patients with different severities of COVID-19 , 2020 .
[17] M. Tay,et al. The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.
[18] R. Woods,et al. Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.
[19] Paolo Maria Matricardi,et al. The first, holistic immunological model of COVID‐19: Implications for prevention, diagnosis, and public health measures , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[20] Nathaniel Hupert,et al. Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.
[21] J. M. Crawford,et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.
[22] Jing Shi,et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan , 2020, Journal of Allergy and Clinical Immunology.
[23] Lei Liu,et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.
[24] Guillermo J. Lagos-Grisales,et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis , 2020, Travel Medicine and Infectious Disease.
[25] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[26] G. Schett,et al. IgA subclasses have different effector functions associated with distinct glycosylation profiles , 2020, Nature Communications.
[27] J. Ravetch,et al. Functional diversification of IgGs through Fc glycosylation. , 2019, The Journal of clinical investigation.
[28] J. Jansen,et al. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG , 2019, Front. Immunol..
[29] Z. Vadasz,et al. Innate immune-responses and their role in driving autoimmunity. , 2019, Autoimmunity reviews.
[30] D. Baeten,et al. The inflammatory function of human IgA , 2018, Cellular and Molecular Life Sciences.
[31] M. van Egmond,et al. IgA Complexes in Plasma and Synovial Fluid of Patients with Rheumatoid Arthritis Induce Neutrophil Extracellular Traps via FcαRI , 2016, The Journal of Immunology.
[32] S. Klein,et al. Sex differences in immune responses , 2016, Nature Reviews Immunology.
[33] Cornelia L Dekker,et al. Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching , 2016, eLife.
[34] E. Cornelio. Situation Report , 2012 .
[35] J. Köhl,et al. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. , 2012, Immunobiology.
[36] P. Woo,et al. Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS Coronavirus , 2004, Clinical Diagnostic Laboratory Immunology.
[37] J. Lund,et al. FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy , 1997 .
[38] J. Lund,et al. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. , 1997, Blood.